FDA Clearance Tracker · P150031-S040
Vercise PC, Vercise Gevia and Vercise Genus DBS Systems
Last checked: Nov 20, 2026Latest source record: Oct 20, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Oct 20, 2021
Approved
Time to decision
232 days
Received Mar 2, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150031-S040
- Device name
- Vercise PC, Vercise Gevia and Vercise Genus DBS Systems
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Mar 2, 2021
- Decided
- Oct 20, 2021
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150031
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval to expand the current IFU to include: "Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM). The device is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability."
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.